 BOSTON--BUSINESS WIRE--Astria Therapeutics, Inc. NASDAQ:ATXS, a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema HAE, today presented Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients, supporting that there is substantial need to address both HAE disease burden and treatment burden with effective therapies that have less frequent dosing. These findings were presented at the 2021 NORD Rare Diseases and 